These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

896 related items for PubMed ID: 19483648

  • 1. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O, Lupu A, Schmidt S, Condomines M, Belle S, Maier A, Hose D, Neuber B, Moos M, Kleist C, Terness P, Ho AD, Goldschmidt H, Klein B, Hundemer M.
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [Abstract] [Full Text] [Related]

  • 2. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
    Hundemer M, Schmidt S, Condomines M, Lupu A, Hose D, Moos M, Cremer F, Kleist C, Terness P, Belle S, Ho AD, Goldschmidt H, Klein B, Christensen O.
    Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
    [Abstract] [Full Text] [Related]

  • 3. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
    Merindol N, Grenier AJ, Caty M, Charrier E, Duval A, Duval M, Champagne MA, Soudeyns H.
    J Immunol; 2010 Jul 15; 185(2):856-66. PubMed ID: 20543110
    [Abstract] [Full Text] [Related]

  • 4. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
    Carrabba MG, Castelli C, Maeurer MJ, Squarcina P, Cova A, Pilla L, Renkvist N, Parmiani G, Rivoltini L.
    Cancer Res; 2003 Apr 01; 63(7):1560-7. PubMed ID: 12670905
    [Abstract] [Full Text] [Related]

  • 5. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.
    J Immunother; 2006 Apr 01; 29(5):545-57. PubMed ID: 16971810
    [Abstract] [Full Text] [Related]

  • 6. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ.
    Clin Cancer Res; 2005 May 01; 11(9):3446-54. PubMed ID: 15867247
    [Abstract] [Full Text] [Related]

  • 7. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.
    Rew SB, Peggs K, Sanjuan I, Pizzey AR, Koishihara Y, Kawai S, Kosaka M, Ozaki S, Chain B, Yong KL.
    Clin Cancer Res; 2005 May 01; 11(9):3377-84. PubMed ID: 15867238
    [Abstract] [Full Text] [Related]

  • 8. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y, Maruyama K, Tai S, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.
    Int J Oncol; 2008 Sep 01; 33(3):433-41. PubMed ID: 18695871
    [Abstract] [Full Text] [Related]

  • 9. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
    van Elsas A, van der Burg SH, van der Minne CE, Borghi M, Mourer JS, Melief CJ, Schrier PI.
    Eur J Immunol; 1996 Aug 01; 26(8):1683-9. PubMed ID: 8765006
    [Abstract] [Full Text] [Related]

  • 10. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
    Jenne L, Arrighi JF, Jonuleit H, Saurat JH, Hauser C.
    Cancer Res; 2000 Aug 15; 60(16):4446-52. PubMed ID: 10969791
    [Abstract] [Full Text] [Related]

  • 11. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D, Dutoit V, Ayyoub M, Rimoldi D, Guillaume P, Liénard D, Lejeune F, Cerottini JC, Romero P, Speiser DE.
    Cancer Immun; 2003 Oct 28; 3():15. PubMed ID: 14580186
    [Abstract] [Full Text] [Related]

  • 12. An antigen-targeted approach to adoptive transfer therapy of cancer.
    Valmori D, Pittet MJ, Rimoldi D, Liénard D, Dunbar R, Cerundolo V, Lejeune F, Cerottini JC, Romero P.
    Cancer Res; 1999 May 01; 59(9):2167-73. PubMed ID: 10232604
    [Abstract] [Full Text] [Related]

  • 13. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    Cancer; 2009 Feb 15; 115(4):800-11. PubMed ID: 19117353
    [Abstract] [Full Text] [Related]

  • 14. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D, Fonteneau JF, Lizana CM, Gervois N, Liénard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P.
    J Immunol; 1998 Feb 15; 160(4):1750-8. PubMed ID: 9469433
    [Abstract] [Full Text] [Related]

  • 15. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition.
    Dutoit V, Guillaume P, Romero P, Cerottini JC, Valmori D.
    Cancer Immun; 2002 Jul 12; 2():7. PubMed ID: 12747752
    [Abstract] [Full Text] [Related]

  • 16. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
    Qian J, Wang S, Yang J, Xie J, Lin P, Freeman ME, Yi Q.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8808-15. PubMed ID: 16361569
    [Abstract] [Full Text] [Related]

  • 17. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.
    Pérez-Díez A, Butterfield LH, Li L, Chakraborty NG, Economou JS, Mukherji B.
    Cancer Res; 1998 Dec 01; 58(23):5305-9. PubMed ID: 9850054
    [Abstract] [Full Text] [Related]

  • 18. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
    Oelke M, Moehrle U, Chen JL, Behringer D, Cerundolo V, Lindemann A, Mackensen A.
    Clin Cancer Res; 2000 May 01; 6(5):1997-2005. PubMed ID: 10815925
    [Abstract] [Full Text] [Related]

  • 19. HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
    Chauvin JM, Larrieu P, Sarrabayrouse G, Prévost-Blondel A, Lengagne R, Desfrançois J, Labarrière N, Jotereau F.
    J Immunol; 2012 Mar 01; 188(5):2102-10. PubMed ID: 22291187
    [Abstract] [Full Text] [Related]

  • 20. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M.
    Cancer Res; 2007 Mar 15; 67(6):2881-92. PubMed ID: 17363612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.